Form 4: Tandem Diabetes Care Executive Trades Common Stock
Statement of Changes in Beneficial Ownership
Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care Inc., reported transactions involving common stock and restricted stock units.
Summary
- Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care Inc. (TNDM), reported several transactions on May 15, 2026.
- These transactions include the acquisition of 1,503 shares of common stock valued at $0, and the acquisition of 1,336 shares through the Employee Stock Purchase Plan (ESPP) at $10.90 per share.
- Additionally, 430, 314, and 1,980 shares were disposed of to cover tax withholding obligations upon the vesting of restricted stock units (RSUs).
- The filing also details the acquisition and vesting schedules for various RSU awards granted in 2023 and 2024.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine executive stock transactions and RSU vesting, which are standard disclosures and do not inherently signal significant positive or negative company performance.
Positives
- Acquisition of 1,503 shares of common stock at no cost.
- Acquisition of 1,336 shares through the ESPP at a favorable price of $10.90 per share.
- Vesting of restricted stock units indicates continued equity-based compensation and potential future value realization for the executive.
Negatives
- Disposal of 430, 314, and 1,980 shares to cover tax withholding obligations, representing a reduction in the executive's direct holdings.
Risks
- The disposal of shares for tax withholding could be interpreted as a need for liquidity by the executive, though this is a standard practice.
- The vesting schedules for RSUs are subject to continued employment and company performance, posing a risk of forfeiture if conditions are not met.
Future Outlook
The filing details vesting schedules for RSU awards granted in 2023, 2024, and 2025, indicating future equity grants and potential future ownership for the reporting person.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The participation in an ESPP and the use of RSUs are common compensation practices within the medical device industry, reflecting a typical alignment of executive interests with shareholder value.
Stakeholder Impact
- Shareholders: The transactions reflect standard executive compensation and do not immediately indicate a change in the executive's overall beneficial ownership that would significantly impact share price, beyond normal market activity.
- Employees: The ESPP participation indicates an opportunity for employees to purchase company stock, fostering a sense of ownership.
- Management: The RSU vesting and ESPP participation align executive interests with the company's performance and stock value.
Next Steps
- Continued vesting of RSU awards according to the specified schedules.
- Potential future transactions by the reporting person based on RSU vesting and ESPP participation.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of earliest transaction reported and transaction date for stock acquisitions and RSU vesting/disposals. |
| 05/15/2024 | Vesting date for 33% of RSU award granted on May 25, 2023. |
| 05/15/2025 | Vesting date for 33% of RSU award granted on May 23, 2024. |
| 05/15/2026 | Vesting date for 33% of RSU award granted on May 30, 2025. |
| 05/19/2026 | Date of filing signature. |
Keywords
Form 4, Tandem Diabetes Care, TNDM, Susan Morrison, Stock Transaction, Restricted Stock Units, ESPP, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.